chartexchange

Sagimet Biosciences Reports Q3 2026 Loss of $0.27 Per Share, Missing Analyst Estimates

GuruFocus | Nov 12, 2026 11:10 AM EST

Clinical-stage biopharma funds operations through mid-2029 with $115 million October offering Related Stocks: SGMT ,

Read original article